Scholarlink

Background <p>Dasatinib, a second-generation tyrosine kinase inhibitor widely used for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), has been reported in association with rare cases of chylothorax.</p> Objective <p>To systematically summarize published case reports and complement these findings with pharmacovigilance data in order to characterize the clinical presentation, management, and outcomes of dasatinib-associated chylothorax.</p> Methods <p>A scoping review was conducted in accordance with PRISMA 2020 recommendations. PubMed/MEDLINE and an institutional discovery platform were searched for case reports and case series published up to February 13, 2026. Eligible reports included patients developing chylothorax during dasatinib therapy. In parallel, data from the FDA Adverse Event Reporting System (FAERS) were analyzed through September 30, 2024. Descriptive analyses were performed. FAERS data were interpreted as hypothesis-generating only.</p> Results <p>Forty-two publications describing 44 patients met the inclusion criteria. Patients ranged from 5 to 90&#xa0;years of age, with a slight male predominance. Time from dasatinib initiation to chylothorax onset varied from 2&#xa0;months to 10&#xa0;years. Management most commonly involved drug discontinuation and thoracentesis, frequently followed by clinical resolution. FAERS analysis identified 104 unique reports of chylothorax associated with dasatinib, all classified as serious adverse events; severe outcomes were uncommon. Reporting trends increased over time, particularly between 2017 and 2023.</p> Limitations <p>Evidence derives from case reports and spontaneous reporting data, which do not allow estimation of incidence or causal inference and are subject to reporting bias and incomplete information.</p> Conclusions <p>Dasatinib-associated chylothorax is an uncommon but clinically relevant event that may occur even after prolonged therapy. Long-term monitoring and prompt recognition are essential. Findings from pharmacovigilance data should be interpreted cautiously and considered hypothesis-generating. Further studies using large retrospective administrative databases are warranted to formally evaluate this potential association.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月11日

查看全文
  • Eleonora Castellana,
  • Patricia Madalina Budau,
  • Cecilia Miglietta,
  • Paola Milla,
  • Maria Rachele Chiappetta

摘要

Background

Dasatinib, a second-generation tyrosine kinase inhibitor widely used for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), has been reported in association with rare cases of chylothorax.

Objective

To systematically summarize published case reports and complement these findings with pharmacovigilance data in order to characterize the clinical presentation, management, and outcomes of dasatinib-associated chylothorax.

Methods

A scoping review was conducted in accordance with PRISMA 2020 recommendations. PubMed/MEDLINE and an institutional discovery platform were searched for case reports and case series published up to February 13, 2026. Eligible reports included patients developing chylothorax during dasatinib therapy. In parallel, data from the FDA Adverse Event Reporting System (FAERS) were analyzed through September 30, 2024. Descriptive analyses were performed. FAERS data were interpreted as hypothesis-generating only.

Results

Forty-two publications describing 44 patients met the inclusion criteria. Patients ranged from 5 to 90 years of age, with a slight male predominance. Time from dasatinib initiation to chylothorax onset varied from 2 months to 10 years. Management most commonly involved drug discontinuation and thoracentesis, frequently followed by clinical resolution. FAERS analysis identified 104 unique reports of chylothorax associated with dasatinib, all classified as serious adverse events; severe outcomes were uncommon. Reporting trends increased over time, particularly between 2017 and 2023.

Limitations

Evidence derives from case reports and spontaneous reporting data, which do not allow estimation of incidence or causal inference and are subject to reporting bias and incomplete information.

Conclusions

Dasatinib-associated chylothorax is an uncommon but clinically relevant event that may occur even after prolonged therapy. Long-term monitoring and prompt recognition are essential. Findings from pharmacovigilance data should be interpreted cautiously and considered hypothesis-generating. Further studies using large retrospective administrative databases are warranted to formally evaluate this potential association.